Drug Profile

Fanotaprim - Vyera Pharmaceuticals

Alternative Names: TRC-2533; TRC-2533-NX; TUR-006; VYR-006

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vyera Pharmaceuticals
Class Antiparasitics; Diamines; Ethers; Piperazines; Pyrimidines; Small molecules
Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2025 No recent reports of development identified for phase-I development in Toxoplasmosis in Canada (PO, Capsule)
04 Jan 2023 Fanotaprim is still in phase I trials for Toxoplasmosis in Canada (Vyera pharmaceuticals pipeline, January 2023)
04 Jan 2023 Vyera pharmaceuticals completes a phase I trial in Toxoplasmosis in Canada, before January 2023 (Vyera pharmaceuticals pipeline, January 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com